INTRODUCTION
The tumor suppressor p53 serves to maintain genomic integrity and regulates the expression of multiple genes that are engaged in cell cycle, apoptosis and metabolism (Lane and Levine, 2010; Vousden and Prives, 2009; Wang and Gu, 2014) , as well as immunomodulation (Zitvogel and Kroemer, 2015) . It is inactivated in over half of all human cancers via genetic mutations, or MDM2/MDMX-or human papilloma virus (HPV) E6-mediated degradation (Levine and Oren, 2009; Vogelstein and Kinzler, 2004; Vousden and Prives, 2009) . Nevertheless, there are some tumor types where these mechanisms of p53 tumor suppressor pathway inactivation do not frequently occur at the time of diagnosis. One such tumor is neuroblastoma (Molenaar et al., 2012; Pugh et al., 2013) , the most common pediatric extracranial solid malignancy, responsible for $15% of cancer deaths in children (Maris, 2010) .
Accumulating evidence has implicated epigenetic changes as drivers of cancer (Chi et al., 2010; Dawson and Kouzarides, 2012; Greer and Shi, 2012; Kaelin and McKnight, 2013; Suva et al., 2013; Vogelstein et al., 2013) , with many of these being due to alterations in the activity of histone lysine demethylases (KDM) (Dawson and Kouzarides, 2012; Greer and Shi, 2012; Kooistra and Helin, 2012) . Several studies indicate that histone demethylases are involved in the regulation of p53 activity. KDM1A has been shown to remove the methyl groups from lysine 370 (K370me2) of the p53 protein directly, thereby suppressing its transcriptional activity (Huang et al., 2007) . PHF2 facilitates p53-mediated cell death in response to chemotherapy (Lee et al., 2014) , whereas KDM6B can be recruited to p53-bound promoters and enhancer elements with unknown function (Williams et al., 2014) . Nevertheless, the roles of other histone demethylases in the regulation of p53 activity have not been well defined. Interestingly, a recent study has shown that methyltransferase SETD8 inhibits the p53 pathway by modulating p53K382me1 levels in high-risk neuroblastoma (Veschi et al., 2017) , supporting the hypothesis that additional mechanisms may be involved in the regulation of p53 function in neuroblastoma.
KDM5A (also referred to as RBP2 or JARID1A), an H3K4me3/me2 histone demethylase (Christensen et al., 2007; Klose et al., 2007) , is a potential oncogene that is highly expressed in many different cancers , supports a stem-like phenotype in cancer cells (Sharma et al., 2010) , and promotes therapy resistance (Banelli et al., 2015; Hou et al., 2012; Sharma et al., 2010) . Genetic ablation of KDM5A hinders tumorigenesis and metastasis (Cao et al., 2014; Lin et al., 2011; Teng et al., 2013) . KDM5A is also involved in tumor angiogenesis (Li et al., 2014; Qi et al., 2014) . Interestingly, KDM5A can be fused with NUP98 in over 10.5% of pediatric acute megakaryoblastic leukemia (de Rooij et al., 2013; van Zutven et al., 2006) . A murine model demonstrated that NUP98/KDM5A is oncogenic in leukemogenesis (Wang et al., 2009) . In this study, we examined the effect of all human histone demethylases on p53 activity and found that (1) several KDMs including KDM5A play a role in modulating p53 function; (2) KDM5A is amplified in many types of cancers, an event that tends to be mutually exclusive to p53 gene mutations; (3) KDM5A is overexpressed in highstage and high-risk neuroblastomas, is associated with a poor outcome, and is negatively correlated with expression of p53 target genes; (4) loss of KDM5A significantly enhances p53 protein accumulation and inhibits tumor growth in wild-type p53, but not mutant p53-expressing colon cancer and neuroblastoma xenograft models; and (5) KDM5A inhibits p53 protein synthesis by suppressing the expression of a subgroup of protein translation genes. We also identified a signaling pathway between KDM5A and miR-34, a p53 target gene that is frequently deleted in high-risk neuroblastomas. Thus, our findings not only support a mechanism by which KDM5A regulates p53 function but also provide a rationale for targeting KDM5A in cancers with wild-type p53.
RESULTS

Identification of Histone Demethylases that Modulate p53 Function
One of the most well-characterized p53 targets is CDKN1A (also known as p21), which bears two p53 binding sites (5 0 RE and 3 0 RE) in the promoter region (Zeng et al., 1997) . We therefore used a luciferase reporter carrying the 5 0 RE and 3 0 RE of CDKN1A to monitor changes in p53 activity that might be affected by altering histone demethylase expression ( Figure 1A ). We used a focused pooled small interfering RNA (siRNA) library (Yang et al., 2017 ) (including 32 genes encoding JmjC domain proteins with 17 of them having histone lysine or arginine demethylase activity and 2 genes encoding FAD-dependent demethylases, KDM1A and KDM1B) to demonstrate histone demethylase activity in isogenic p53 +/+ and p53 À/À HCT116 colon cancer cell lines. These isogenic cell lines allowed us to assess the p53-dependent effects only since CDKN1A could be activated by other p53-independent epigenetic events such as histone deacetylase (HDAC) inhibition (Gui et al., 2004) . We also transfected a Renilla luciferase reporter to serve as an internal control to normalize the CDKN1A firefly luciferase. We identified that depletion of KDM4D, KDM5A, KDM6B, PHF2, PHF8, C14orf169, and JMJD4 resulted in at least a 2-fold greater induction of CDKN1A luciferase activity in p53 +/+ HCT116 cells compared with p53 À/À HCT116 cells ( Figure 1B ). Here we focused on KDM5A for the reasons described below and therefore validated KDM5A-mediated p53 activity. We designed single siRNA oligos and performed RT-PCR. The results showed that depletion of KDM5A led to significant induction of CDKN1A in p53 +/+ HCT116 cells ( Figure 1C ), consistent with the reporter assay screening.
KDM5A Is Amplified in Several Different Cancers and Is Negatively Correlated with p53 Genetic Mutations
To assess whether any genomic alterations of the KDMs were associated with changes in p53 function, we first examined the genomic amplification or loss of KDMs, since these are important mechanisms by which cancer cells activate proto-oncogenes or inactivate tumor suppressors, using the Tumorscape program, which has high-resolution copy number data amassed from multiple cancer types (all generated through TCGA) (Beroukhim et al., 2010) . We found that the KDM5A gene was significantly focally amplified across the entire dataset of 10,844 tumors and was located within a focal peak region of the amplicons (q value = 1.91 3 10 À33 ) ( Figure 1D and Table S1 ). KDM5A is significantly focally amplified in 12 of 33 independent cancer types (Table S2 ). Among these, it is located within a focal peak region of amplification in 11 cancer types (Table S2) . Interestingly, after analysis of the tumors from TCGA-PAN cancer data that were well characterized for genetic alterations of KDM5A, MDM2, and TP53, we found that KDM5A is significantly associated with genetic mutations of TP53 ( Figure 1E ). Interestingly, tumors with KDM5A amplification tended to be enriched with wild-type p53 when compared with those with KDM5A loss (Figures 1E and 1F and  Table S3 ), similar to MDM2 amplification/loss ( Figure 1F ). Furthermore, by using the cBioPortal program (Cerami et al., 2012; Gao et al., 2013) we combined five different types of cancer cohorts that had higher incidence of KDM5A amplification (>5%, Figure S1A ) for analyses of genetic alteration data of TP53, KDM5A, MDM2, and CDKN2A (P14ARF) ( Figure 1G ). p14Arf is a classical tumor suppressor that antagonizes MDM2, thereby playing an important role in regulating p53 protein expression (Kamijo et al., 1998; Stott et al., 1998; Zhang et al., 1998) . Among these genetic alterations, despite a tendency of co-occurrence genetic events between KDM5A and MDM2 ( Figure 1H ), KDM5A and MDM2 amplification tended to be mutually exclusive to TP53 mutations ( Figure 1H ). These genetic data suggest that, given the prevalence of its amplification in a variety of human cancers but the negative enrichment with p53 mutations, KDM5A might be a potential proto-oncogene in some types of cancers and may act on the p53 signaling pathway.
KDM5A Overexpression Occurs in High-Stage and High-Risk Neuroblastoma and Is Associated with a Poor Prognosis
The genetic amplification of oncogenes often leads to mRNA overexpression. We assumed that aberrant overexpression of KDM5A through mechanisms other than amplification may also be negatively correlated with p53 function. Neuroblastoma, the most common extracranial solid cancer in childhood, rarely bears genetic alterations of p53 (as well as p14Arf or MDM2) at diagnosis (Molenaar et al., 2012; Pugh et al., 2013) . We, therefore, speculated that KDM5A might be important in neuroblastoma pathogenesis by suppressing p53 activity. Although amplification of KDM5A does not appear to be a common event in neuroblastoma, overexpression of the KDM5A gene was significantly higher in patients with stage 4 disease than in those with other stages, according to the RNA sequencing (RNA-seq) data from a cohort of 498 patients (Su et al., 2014) (Figure 2A ). KDM5A was also significantly overexpressed in high-risk disease ( Figure 2B ). In addition, Kaplan-Meier analysis showed that high KDM5A expression (median value as a cutoff for KDM5A expression levels) was associated with poor outcome in children with neuroblastoma ( Figure 2C ).
KDM5A Inhibits p53 Signaling
Since KDM5A was highly expressed in high-risk neuroblastomas, we first characterized the function of KDM5A in neuroblastoma, by performing a global gene expression profile analysis after depletion of KDM5A in human neuroblastoma cells. Gene set enrichment analysis (GSEA) showed that depletion of KDM5A in NB-1691 cells (wild-type p53) resulted in induction of the p53 targets ( Figure 2D ) and negatively correlated with the gene signature upregulated after p53 knockdown ( Figure 2E ). However, there was no change in the p53 signaling pathways after KDM5A depletion in BE2(C) cells that have mutant p53 (Tweddle et al., 2001) . Western blot analysis revealed that p53 and its target p21 were both induced by depletion of KDM5A in NB-1691, SK-N-SH, and IMR32 cells ( Figure 2F ), three cell lines with wild-type p53. Interestingly, we also observed induction of mutant p53, but not p21, in BE2(C) cells ( Figure 2G ), suggesting that KDM5A overexpression correlates with reduced p53 expression regardless of its mutation status. We further assessed the correlation of KDM5A and p53 targets. We chose several well-studied p53 target genes including CDKN1A, BBC3 (also named PUMA), BAX, and GDF15, which play important roles in cell-cycle arrest and apoptosis. The results showed that these genes were significantly negatively correlated with KDM5A overexpression ( Figures 2H and 2I ), supporting the hypothesis that KDM5A suppresses p53 function in neuroblastoma. To further assess the role of KDM5A in p53-mediated tumor suppression, we established stable KDM5A depletion using lentiviral small hairpin RNA (shRNA) in NB-1691, SK-N-SH, and BE2(C) cells for xenograft studies. Transduced cells containing the shRNAs were selected for in the presence of 1 mg/mL of puromycin to eliminate the non-transduced cells. KDM5A depletion led to significant tumor growth delay in p53 wild-type cancer cell lines NB-1691 and SK-N-SH ( Figures 2J and 2K ) but not the p53 mutant BE2(C) cell line ( Figure 2L ), in accordance with induction of p53 targets before the establishment of xenografts ( Figures 2J-2L ).
To address whether the above findings represented a general mechanism across different cancer lineages, we included several different types of cancer cell lines bearing wild-type p53 or no p53. First, we performed GSEA after depletion of KDM5A in p53 +/+ and isogenic p53 À/À HCT116 colon cancer cells. Again, this revealed that KDM5A loss resulted in high activity of p53 pathways in p53 +/+ HCT116 cells ( Figures 3A-3C) but not in p53 À/À HCT116 cells ( Figure S1B ). Molecular concept analysis further demonstrated that loss of KDM5A function in p53 +/+ HCT116 cells led to the expression of genes associated with various p53 signatures, as well as chemotherapy-and ionizing-radiation-induced signatures ( Figure 3D ). We then assessed protein expression of p53 targets and found that p21, PUMA, TIGAR, and MDM2 were upregulated after KDM5A depletion across several types of cancer cell lines including colon cancer, osteosarcoma, and lung cancer ( Figures 3E-3G ), in accordance with the induced p53 protein, demonstrating the ability of KDM5A to suppress p53 signaling in a wide variety of human cancer cell lines. The induction of p53 by loss of KDM5A was further validated by knocking out KDM5A using CRISPR/Cas9 at two different genomic loci of the KDM5A gene from five individual clones that were derived from single cells ( Figure S1C ). Conversely, overexpression of KDM5A reduced p53 expression, and its target p21 expression ( Figure 3H ). We further assessed the expression of KDM5A and p53 target genes in a variety of different types of cancer cohorts. The results showed that KDM5A overexpression was negatively correlated with the expression of p53 targets ( Figures 3I-3L , and data not shown), suggesting that repression of p53 activity by KDM5A is common across many cancers. Consistent with the tumor suppressive functions of p53, depletion of KDM5A significantly reduced cell colony formation in p53 +/+ but not p53 À/À cancer cells ( Figures S1D and S1E ). We also generated lentiviral-mediated shRNA knockdown of KDM5A in isogenic p53 +/+ and p53 À/À HCT116 cells ( Figure 3M ), which allowed us to evaluate the p53 effect more specifically. Again, depletion of KDM5A resulted in significant reduction of tumor growth in the p53 +/+ but not in the p53 À/À xenografts ( Figure 3M ).
Interestingly, after analysis of the expression of KDM5A and p53 in three HCT116 xenografts per group that were randomly chosen, we found that KDM5A re-expressed in all tumor samples of p53 +/+ HCT116 but not in p53 À/À HCT116 and p53 expression was restored back to the same levels as the control ( Figure 3N ), suggesting that shRNA knockdown of KDM5A confers a selective pressure on p53 wild-type cells, or that it was (B) GSEA shows that genes upregulated after KDM5A depletion in p53 +/+ HCT116 cells is associated with a gene set of Inga p53 targets.
(C) GSEA shows that genes upregulated after KDM5A depletion in p53 +/+ HCT116 cells is associated with a gene set of KEGG p53 signaling pathway. due to selection of rare clones that were not transduced by KDM5A shRNA. We therefore hypothesize that KDM5A may reflect the response of cancer cells to therapies that activate the p53 pathway. Indeed, the data from the Cancer Therapeutics Response Portal (Rees et al., 2016) , which links genetic, lineage, and other cellular features of cancer cell lines to small-molecule sensitivity, showed that cancer cells expressing higher KDM5A were more sensitive to chemotherapeutic drugs such as etoposide, doxorubicin, and cytarabine ( Figure S1F ). However, KDM5B, a paralog of KDM5A, was correlated with drug sensitivity to tyrosine kinase inhibitors and mitogen-activated protein kinase inhibitors ( Figure S1G ). Taken together, these results demonstrate that KDM5A plays an important role in suppressing p53 function in neuroblastoma and other p53 wild-type-expressing tumors, further suggesting that KDM5A is a regulator of the p53 signaling pathway in most cancers if not all. Therefore, in the following studies, we mainly used the HCT116 colon cancer cell line as the model to dissect the molecular mechanism by which KDM5A regulates p53 expression because this cell line is more easily manipulated genetically and pharmacologically.
KDM5A Inhibits p53 Protein Synthesis
We next sought to understand the mechanism by which KDM5A regulates the p53 signaling pathway in cancer cells. To define the mechanism by which KDM5A suppresses p53 expression, we first tested whether KDM5A directly regulates p53 transcription. Real-time PCR revealed that TP53 mRNA was modestly decreased, although CDKN1A was greatly upregulated by KDM5A depletion in p53 wild-type HCT116 cells ( Figure 4A ), suggesting that KDM5A regulates p53 expression at a post-transcriptional level. Normally, p53 is a very labile protein that is subject to proteasomal degradation (Kruse and Gu, 2009) . In response to cellular stress, such as DNA damage, p53 undergoes post-translational modifications such as phosphorylation at serine 15 and serine 20, which result in the displacement of MDM2 from the N terminus of p53, with consequent stabilization of the p53 protein (Toledo and Wahl, 2006) . We found that the DNA-damaging agent doxorubicin induced phosphorylation of p53 Serine 15 but KDM5A depletion did not ( Figure 4B ), nor did it reduce the protein-protein interaction between MDM2 and p53 ( Figure 4C ). KDM5A knockdown also did not significantly alter the half-life of p53 when protein synthesis was blocked by cycloheximide ( Figure 4D , top panel), whereas treatment of cells with doxorubicin and Nutlin-3, a compound that disrupts the p53-MDM2 interaction, significantly stabilized p53 protein ( Figure 4D , bottom panel). These data suggest that KDM5A does not regulate p53 expression through MDM2-mediated degradation. Conversely, when the proteasome inhibitor MG132 was used to block p53 degradation, the amount of newly synthesized p53 protein labeled with S 35 was much greater after KDM5A depletion, although the total newly synthesized and total protein were not (Figures 4E and S2A) , suggesting that KDM5A regulates p53 protein synthesis specifically.
To further validate this, we used alternative approaches to assess the role of KDM5A in the regulation of p53 synthesis. First, we introduced into HCT116 cells a heterologous luciferase reporter in which the p53 coding sequence was replaced by the coding sequence for luciferase, whereas the 5 0 and 3 0 UTRs of p53 remained intact. The mRNA expression of this reporter was driven by a heterologous promoter, but its translation should be regulated by the same machinery as endogenous p53 because the 5 0 -and -3 0 -UTRs of p53 were intact. In these experiments, KDM5A knockdown significantly enhanced the luciferase activity in both p53 +/+ and p53 À/À HCT116 cells ( Figure 4F ), supporting the hypothesis that KDM5A regulates p53 translation. Next, we tested the effect of two compounds, rocaglamide (Roc A) and cymarin, which specifically inhibit protein translation (Didiot et al., 2013; Rodrigo et al., 2012) . We found that when these two compounds were administered, the amount of p53 protein induced by KDM5A depletion was reduced to basal levels, without significantly downregulating p53 mRNA expression ( Figures 4G and S2B) ; however, the p53 protein induced by Nutlin-3 compounds (Nutlin-3b is much less potent than Nutlin-3a), was only partially affected by protein translation inhibitors ( Figure 4G ). These data indicate that inhibition of protein translation reduced KDM5A-depletion-but not Nutlin-3-induced (via p53 stabilization) enhanced p53 expression. Finally, we found that KDM5A depletion resulted in increased p53 expression in RC10.1 cells ( Figure S2C ). Rapid degradation of p53 in this cell line normally occurs because these cells, derived from RKO cells, have been engineered to express the HPV E6 oncoprotein (Kessis et al., 1993) . However, the increased p53 expression in these cells due to depletion of KDM5A partly overwhelmed the degradation by E6, allowing for the detection of p53. Taken together, these data further support our hypothesis that KDM5A inhibits p53 expression via a mechanism that is involved in p53 protein translation. 
KDM5A Regulates the Expression of Genes Involved in Translation
Protein translation can be divided into four phases: initiation, elongation, termination, and ribosome recycling (Bhat et al., 2015) . We sought to determine at what phase KDM5A was acting. Translation initiation is the most important and complicated step of the translation process and involves many factors and multiple complexes ( Figure 5A ). Our gene expression profiling analysis revealed that KDM5A depletion resulted in upregulation of a signature containing genes involved in translation initiation but not other steps of translation ( Figure 5A ), indicating that KDM5A inhibits a subgroup of translation initiation genes. We further analyzed the RNA-seq data from the PAN-CAN dataset and confirmed that expression of KDM5A and EIF2B4, EIF5A, and MTIF3 were inversely correlated ( Figures 5B and 5C ), supporting that KDM5A suppresses the expression of these genes. To explore whether KDM5A was directly involved in the expression of these translation initiation genes, we performed chromatin immunoprecipitation sequencing (ChIPseq) analysis to determine whether KDM5A bound these genes. Our ChIP-seq data revealed that, among the approximately 5,000 genomic regions bound by KDM5A (Table S4) , nearly 100 genes were involved in translation and many of these encoded ribosomal proteins, based on canonical signaling pathway analysis (Table S5 ). Many of these proteins engage in translation initiation ( Figure 5D ). We also analyzed the ENCODE ChIP-seq data in which data on KDM5A genomic binding in human embryonic stem cells are available. We found that the genomic loci of these target genes bound by KDM5A were significantly correlated ( Figures 5D and S3A ), which corroborated our ChIP-seq data.
KDM5A is a histone demethylase that removes H3K4me3/me2. To explore the role of the histone demethylase activity of KDM5A in the regulation of translation initiation genes, we removed KDM5A expression in HCT116 cells using CRISPR/Cas9 and performed ChIP-seq to assess the H3K4me3 changes. The results showed that KDM5A genomic binding sites overlapped with H3K4me3 peaks ( Figure 5D and Table S6 ), and deletion of KDM5A led to an increase in H3K4me3 levels at the promoter regions on these genes (Figure 5D ), in line with its histone demethylase activity. Interestingly, we noticed that H3K4me3 was also upregulated at the locus of TP53 in KDM5A KO cells ( Figure S3B ), despite the mRNA levels of TP53 not being altered in these cells ( Figure 4A ).
To validate whether increased translation initiation was responsible for the upregulation of p53 protein, we studied eIF2B4, the component of the eIF2 complex that regulates the assembly of the 43S pre-initiation complex (PIC) during translation initiation (Bhat et al., 2015) . Knockdown of eIF2B4 prevented the induction of p53 associated with depletion of KDM5A ( Figure 5E ), confirming that KDM5A regulates p53 expression by modulating translation initiation. Interestingly, we also found that downregulation of 4EBP1 due to KDM5A depletion was rescued by co-depletion of eIF2B4 ( Figure 5E ). 4EBP1 inhibits translation initiation by competing with eIF4E, which forms a complex with eIF4A and eIF4G, called eIF4F, leading to 48S PIC assembly (Bhat et al., 2015) . We therefore tested eIF4A2 function and found that loss of eIF4A2 largely rescued the phenotype of p53 induction ( Figure S3C ). eIF4A2 was able to bind the p53 mRNA ( Figure S3D ). We further treated cells with 4E1RCat, a compound that interferes with protein translation initiation by preventing the assembly of the eIF4F complex (Cencic et al., 2011) . The data showed that 4E1Rcat largely rescued the KDM5A effect on p53 protein accumulation ( Figure 5F ), but had no effect on TP53 mRNA expression ( Figure 5G ). To further analyze the correlation of KDM5A targets with signaling pathways, we used a connectivity map to compare the transcriptome of KDM5A with gene profiles resulting from gene knockdown, gene overexpression, or compound treatment. Despite the upregulation of a subgroup of translation genes ( Figure 5A ), the top hits highly correlated with KDM5A knockdown-induced transcriptomes were global protein synthesis inhibitors including emetine, verrucarin-a, and homoharringtonine (Table S7) . Taken together, these data indicate that KDM5A regulates p53 translation by modulating the expression of protein translation genes.
Enhanced p53 Protein Expression after KDM5A Deletion Is Directly Regulated through Protein Synthesis of TP53
Although we had used pulse-chase with S 35 labeling to show that KDM5A regulates p53 protein synthesis ( Figure 4E ), we further investigated the mechanism by using two approaches: (1) polysomal profiling to assess whether TP53 mRNA is more enriched in polysomes (high translation efficiency) than monosomes (low translation efficiency) and (2) Click-iT labeling to assess the newly synthesized p53 protein and total new proteins after KDM5A knockout ( Figure 6 ). The results showed that p53 expression was greatly increased after KDM5A knockout ( Figure 6A ), consistent with results obtained by siRNA and shRNA of KDM5A. We then used a sucrose gradient (5%-50% of sucrose) method to perform the polysome fractionation ( Figure 6B ) and extracted total RNA from each fraction ( Figure 6C ), followed by quantification of the percentage of TP53 mRNA in each fraction ( Figure 6D ). Indeed, KDM5A deletion resulted in an enrichment of TP53 mRNA in the heavy polysome fractions ( Figure 6D ), suggesting a higher rate of p53 protein synthesis. Importantly, KDM5A knockout had no effect on the total steady-state p53 mRNA levels ( Figure 6E ).
The Click-iT labeling, a similar approach to S 35 pulse labeling, uses a methionine analog L-azidohomoalanine (AHA) to label newly synthesized proteins after methionine-free medium starvation ( Figure 6F ). Then a Click-iT chemistry-based reaction brings the alkyne-modified biotin to the AHA-incorporated polypeptides. The total p53 proteins, including old (non-labeled) and new (labeled) proteins, are immunoprecipitated, followed by immunoblotting for biotin and p53. The biotin antibody only detects newly synthesized p53 that was pulled down. Consistent with S 35 radioactive labeling, the Click-iT labeling assay also showed that p53 protein synthesis was increased by KDM5A knockout ( Figure 6G ). However, the total new proteins were not affected by KDM5A deletion ( Figure 6H) , similar to what we have seen previously ( Figure 4E ). These data indicate that KDM5A specifically regulates p53 protein translation by modulating its mRNA protein synthesis.
miR-34 Inhibits KDM5A Expression
Despite the importance of KDM5A, how it is regulated in cells is not clear. To determine what genetic factors might, in turn, regulate KDM5A expression, we analyzed published neuroblastoma microarray datasets with well-characterized genetic lesions and found that upregulation of KDM5A is correlated with loss of heterozygosity (LOH) of 1p36 and 11q23 in patients with neuroblastoma ( Figure 7A ). Interestingly, members of the miR-34 family of microRNAs (miRNAs), known to be direct targets of p53 (He et al., 2007) and mimics of which were being tested in a clinical trial for hepatocellular carcinoma, reside within these regions; miR-34a is located on chromosome 1p36, whereas its paralogs, the miR-34b/c cluster, is located on chromosome 11q23. LOH or silencing in either or both of these regions is common in a variety of human cancers (Bader, 2012) , including neuroblastoma (Attiyeh et al., 2005) , suggesting that these miRNAs may have a critical role in oncogenesis as tumor suppressors (Bader, 2012) . To assess the functional link between miR-34 and KDM5A, we introduced miR-34 precursors into several neuroblastoma cell lines. Western blot analysis on protein from transfected cells showed that expression of KDM5A was downregulated by miR-34, suggesting that miR-34 targets KDM5A ( Figure 7B ). To further confirm the specificity of miR-34 in the regulation of KDM5A expression, we used an anti-miR to block miR-34 function, resulting in rescue of the expression of KDM5A ( Figure 7C ). The BE2(C) cell line has no detectable miR-34 expression (data not shown), and thus, introduction of anti-miR-34 into these cells has little effect on KDM5A expression.
To determine whether the induction of miR-34, through activation of p53, was able to recapitulate the signature of direct introduction of miR-34 precursors, HCT116 and RKO cells were treated with Nutlin-3 or doxorubicin ( Figures 7D and S4A ). Induction of p53 resulted in upregulation of miR-34 ( Figures 7E  and 7F ) and concomitantly, downregulation of KDM5A ( Figure 7D ). Importantly, this was p53 dependent as depletion of p53 rescued the phenotype ( Figures 7D-7F ). We also found that activation of p53 in the neuroblastoma cell line NB-1691 caused upregulation of miR-34, but knockdown of p53 in these cells diminished these effects ( Figure S4B ), indicating a general mechanism. Importantly, introduction of miR-34 into HCT116 cells significantly upregulated p53 expression ( Figure 7G ). These data support our findings that miR-34 targets KDM5A through a p53-dependent process and suggest that a feedback loop exists. Indeed, KDM5A also regulated miR-34 in a p53-dependent manner with KDM5A knockdown resulting in miR-34 induction in p53 +/+ but not in p53 À/À cells ( Figure 7H ). Moreover, genes regulated by KDM5A
were significantly enriched in the miR-34b/c signature revealed by GSEA analysis, further supporting the relationship between miR-34 and KDM5A ( Figure S4C ). In addition, we confirmed that KDM5B, another member of KDM5 family, was not affected by either doxorubicin or p53 knockdown ( Figure S4D ), indicating that KDM5A is specifically involved in the p53 pathway.
DISCUSSION
p53 is commonly mutated in many different types of cancer. In addition, the classical p14Arf-MDM2 pathway plays an important role in regulating p53 protein expression (Kamijo et al., 1998; Stott et al., 1998; Zhang et al., 1998) ; this pathway is frequently deregulated in cancer. Nevertheless, some types of cancers such as neuroblastoma rarely bear p53 somatic mutations or alterations of the p14Arf-MDM2 pathway (Molenaar et al., 2012; Pugh et al., 2013) , indicating that other mechanisms may exist that suppress p53 function in these cancers (Veschi et al., 2017) . With the identification of the first true histone demethylase KDM1A/LSD1 (Shi et al., 2004) , which is able to modulate p53 methylation, another class of JmjC histone demethylases has been shown to be deregulated in multiple cancers (Kandoth et al., 2013) . However, the roles and working mechanisms of these histone demethylases in cancer have not been fully characterized. In this study, we identified several histone demethylases (KDM4D, KDM5A, KDM6B, PHF2, PHF8) and two additional JmjC-domain-containing proteins (C14orf169 and JMJD4) that are involved in regulating p53 activity. KDM4D is an H3K9me3/me2 demethylase and is able to induce p21 expression (Kim et al., 2012) . However, overexpression of KDM4D causes global demethylation of H3K9me3, which may result in DNA damage and subsequent p53 activation. Similarly, loss of KDM4D may also result in a DNA damage response (Khoury-Haddad et al., 2015) , and thus, activation of p53. KDM6B is an H3K27me3/me2 demethylase and can be recruited to p53-bound promoters and enhancer elements with unknown function (Williams et al., 2014) . It is possible that KDM6B suppresses p53 function in this scenario. Although the histone demethylase activity of PHF2 is not definite, it has been shown to facilitate p53-mediated cell death in response to chemotherapy (Lee et al., 2014) . PHF8 is an H3K9me2/me1 and H4K20me1 demethylase, but how it regulates p53 activity needs further studies. C14orf169 and JMJD4 may not have histone demethylase activity, and no previous studies show that they are involved in p53 function.
Although most genetic mutations in the coding sequences of TP53 disrupt the functions of p53, a rare polymorphism (rs78378222) in the 3 0 -UTR of TP53, which affects p53 protein translation, was found to confer susceptibility to multiple cancers, including neuroblastoma (Diskin et al., 2014; Stacey et al., 2011) . These data suggest that repression of p53 protein translation contributes to oncogenesis. Here we found that the histone demethylase KDM5A was amplified in many types of cancers, and this was negatively correlated with TP53 mutation when compared with KDM5A loss. Most interestingly, we found that KDM5A regulates p53 function by inhibiting p53 protein translation, which may explain why KDM5A amplification is negatively correlated with TP53 mutation. A previous study had shown that ribosomal protein L26 (RPL26) and nucleolin could bind the 5 0 -UTR of p53 mRNA to control p53 translation and induction after DNA damage (Takagi et al., 2005) . RNPC1 has been reported to repress p53 translation in lymphomas (Zhang et al., 2011) . However, our data did not show a significant change in RNPC1, RPL26, or nucleolin expression after depletion of KDM5A, and loss of KDM5A did not induce a significant DNA damage response as assessed by measuring phosphorylated p53, suggesting that KDM5A works through a different mechanism. Indeed, KDM5A negatively regulated a subgroup of genes that are involved in translation initiation such as EIF5A and EIF2B4. Since depletion or knockout of KDM5A had no effect on global protein synthesis based on the assessment of newly synthesized proteins by using S 35 labeling ( Figure 4E ) and Click-iT labeling technology (Figure 6 ), we speculate that two possible mechanisms (which are not mutually exclusive) may account for p53 synthesis regulated by KDM5A: (1) KDM5A regulates a specific program that alters the stoichiometry of translational complex components such as EIF2B4, leading to the activation of a specific translation machinery that promotes p53 synthesis. (2) Specific secondary structures of TP53 mRNA, as reported previously (Candeias et al., 2008; Fu et al., 1996; Ray et al., 2006) , respond to the translation machinery induced by KDM5A. However, other additional mechanisms may exist; hence more studies are needed. In addition, whether there are other mRNAs whose translation is subject to KDM5A knockdown needs to be determined in the future.
Interestingly, by mining a database of a genome-scale genetic interaction map in yeast (Costanzo et al., 2010) , we found that there was a positive genetic interaction between TIF5 and JHD2, the homologs of eIF5 and KDM5A in mammals; that is, the phenotype of TIF5 mutant was partially rescued by JHD2 mutation. Translation initiation factor eIF5 functions to regulate eIF2 activity. Although yeast does not have the p53 tumor suppressor gene, this may indicate that there is an evolutionarily conserved function for KDM5A in the regulation of protein translation. Consistent with the regulatory mechanism of KDM5A, expression of mutant p53 is also enhanced by loss of KDM5A. Mutation in p53 can be seen as a late event in multiple recurrent, chemotherapy-resistant cancers such as neuroblastoma (Keshelava et al., 2000) , and mutant p53 may have additional, direct oncogenic actions that are different from the results of inhibiting p53 signaling early on in tumor progression (Muller and Vousden, 2014) . Considering the context-dependent features of epigenetic modifiers in cancer, under some circumstances, loss of function of KDM5A might afford an additional growth advantage to affected cells with mutant p53. Despite the observation that KDM5A amplification tends to be mutually exclusive to TP53 mutation, there were a fraction of tumors showing co-occurrence of KDM5A amplification and TP53 mutation. This may suggest that either KDM5A has p53-independent function or that amplification of KDM5A confers selective pressure on p53, leading to p53 mutation during cancer progression. Nevertheless, genetic deletion of p14Arf and amplification of MDM2, two classical modulators of p53, also frequently overlap with TP53 mutations.
Although the mechanism by which KDM5A regulates the expression of its targets needs a deeper understanding, we found that KDM5A was located in the promoter regions of its downstream targets from both our own ChIP-seq data and ENCODE data and correlated with changes of the H3K4me3 mark, which is representative of active gene transcription. These data indicate that KDM5A directly regulates the expression of these genes. Previous studies also show that KDM5A can exert biological functions in a histone-demethylase-independent manner (Cao et al., 2014; DiTacchio et al., 2011; Secombe and Eisenman, 2007) . Whether KDM5A regulates p53 translation through its histone demethylase activity needs to be further addressed in the future by using a potent and specific inhibitor.
Although p53 significantly induces p21 after KDM5A depletion, interestingly, we observed some induction of p21 expression in p53-null cells after the loss of KDM5A. The mechanism for this also needs to be further investigated. A recent study shows that KDM5A interacts with the nucleosome remodeling and deacetylase (NuRD) complex (Nishibuchi et al., 2014) , which usually exerts gene repressive functions (Denslow and Wade, 2007) , and HDAC is one of the core components of the NuRD complex (Denslow and Wade, 2007) . It is well known that HDAC inhibitors induce p21 expression (Gui et al., 2004 ), so we speculate that KDM5A may modulate HDAC activity to suppress p21 induction, regardless of the p53 status.
We also found that miR-34s (transcriptional targets of p53) target KDM5A expression (Figure 7) . A recent study showed that miR-34 targets MDM4 (Okada et al., 2014), which facilities MDM2-mediated function, resulting in p53 stabilization. Thus, miR-34 seems to bridge p53 protein stability and translation, thereby enhancing p53 activity ( Figure 6I ). Although this might suggest a feedback loop among these molecules, studies need to delve into more depth to consolidate this interesting observation.
In summary, we have identified a mechanism by which the histone demethylase KDM5A regulates p53 expression by modulating its translation initiation. Targeting KDM5A might be an option for treating p53 wild-type cancers.
Limitations of the Study
Our study has several limitations. First, the mechanism by which KDM5A affects the expression of a set of mRNA translation factors that controls p53 synthesis needs to be further investigated. Second, other messenger RNAs, in addition to p53, are likely to be regulated by KDM5A at the translational level; this needs to be investigated in future studies. In addition, the lack of a specific small-molecule KDM5A inhibitor prevents additional validation of the effect of KDM5A inhibition on tumor growth in the xenograft model. Last, the regulation of KDM5A by miR-34 also needs further in-depth studies to understand the upregulation of p53 by miR-34.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
DATA AND SOFTWARE AVAILABILITY
All microarray and deep sequencing data have been deposited in GEO under accession number: GSE45967, GSE49854, GSE100511, GSE107221. 
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The authors declare no competing interests. RKO and RC10.1 (Michael Kastan, Durham, NC) , A594, H1299, U2OS, SAOS2 (ATCC) cells were maintained in DMEM medium, supplemented with 10% FCS (HyClone, Thermo), 1% L-glutamine (MediaTech), 1% penicillin-streptomycin (Lonza), at 37 °C in 5% CO 2 . IMR32, BE2(C), SK-N-SH and NB-1691 cells were maintained in RPMI medium supplemented with 10% FCS (HyClone, Thermo), 1% L-glutamine (MediaTech), 1% penicillin-streptomycin (Lonza). Cell lines were characterized by Short Tandem Repeat (STR) analysis by using Promega PowerPlex 16 HS System.
Identification of KDMs modulating p53 activity using focused siRNA library After 24-hour plating of 2 X 10 5 of isogenic p53+/+ and p53-/-HCT116 cells in a 6-well plate, the p21-luciferease reporter (0-Luc, Addgene, plasmid#21723) (Zeng et al., 1997b) with the pRL Renilla luciferase control reporter vector (Promega) were transfected using Lipofectamine LTX reagent (Invitrogen). 24-hour later after reporter transfection, the siRNAs (Dharmacon) were reverse transfected using RNAiMax and plated into 96-well plate to a final concentration of 25 nM. After 72-hour siRNA transfection, dual-luciferase reporter assay was performed according to the instruction of manufacturer (Promega). The luciferase reading was done with BioTek. The p21-luciferase was normalized by renilla luciferase, which was then normalized with the nontargeting control 1 (NT1). Then the value for each gene was normalized with the value in p53 -/-HCT16 cells. We picked up the genes as candidates with 2-fold induction as the threshold.
Transfection of miRNA and siRNA oligos
The Pre-miR™ miRNA Precursor molecules (hsa-miR-34a, hsa-miR-34b, hsa-miR-34c, and the control) are small, chemically modified double-stranded RNA molecules designed to mimic endogenous mature miRNAs, and were purchased from Ambion. The anti-miR-34s were purchased from Ambion. siRNA oligos for knockdown of p53, KDM5A, EIF2B4, and firefly luciferase control or Dharmacon Non-targeting control were synthesized by Dharmacon, Thermo Scientific. miRNAs or siRNAs were reversely transfected using RNAiMAX (Invitrogen) for 72-hour according to the manufacture's protocol. siKDM5A#1: UGACAAUGGUGGACCGCAU siKDM5A#4: GGAAAUACCCAGAGAAUGA, siTP53:GCAUCUUAUCCGAGUGGAA, siEIF2B4#1: GAGAUGUGAUCCUGGUAUA, siEIF2B4#3: AGCAGGUGAUUCAGGAUUA.
shRNA transduction
The TRC lentiviral-based shRNA knockdown plasmids for KDM5A were purchased from Open Biosystems, Thermo Scientific. TRCN0000014629 (5-TAAGTGTCCCTGTAAGTCTGG-3) had the best knockdown efficiency, and so was used in the in vivo experiments. The lentiviral shKDM5A and shControl (pLKO.1) particles were packaged by Vector Lab at St Jude. Briefly, HEK293T cells were transfected with shRNA constructs and helper plasmids (pCAG-kGP1-1R, pCAG4-RTR2, and pHDM-G). The 48-and 72-hr post-transfection replication-incompetent lentiviral particles were harvested and transduced into cells with 8µg/ml of polybrene. 48 hours later, 1 µg/ml of puromycin was added for selection for additional 48 hours before injection into mice or immunoblotting.
CRISPR/Cas9
The CRISPR/Cas9 system was used to truncate the KDM5A locus by targeting exons within the catalytic JmjC domain or PHD domain. After extensive bioinformatics analysis of the KDM5A locus integrated with data from ChIP-seq of histone marks, PAM sequences and off-target algorithm, we designed 2 different sgRNAs. The sgRNA sequences targeting exon 11: tctctggtatgaaagtgccg, which targets the JmjC domain of KDM5A; exon16 sgRNA: acgactgacccaagtgtcat, which targets the region between JmjC and the second PHD domains. The paired DNA oligonucleotides containing sgRNA sequences were annealed and cloned into a PX458 (SpCas9-2A-EGFP-U6-sgRNA, Addgene 48138) all-in-one backbone. Clones were verified by Sanger sequencing using the U6 promoter forward primer 5'-gagggcctatttcccatgat-3'. All correct constructs were transfected into p53+/+ HCT116 cells and sorted for GFP. Single cell derived clones were validated for bi-allelic mutations via western blotting.
Immunoprecipitation
After 48h knockdown of KDM5A, HCT116 cells were lysed in immunoprecipitation buffer (25 mM Tris-HCl, pH7.5, 150 mM NaCl, 1 µM EDTA, 5% Glycerol, 1% NP40) with complete protease inhibitors (Roche) and phosphatase inhibitors (Roche) on ice. The pre-cleared lysates were incubated with 2 µg of mouse IgG (Cell Signaling), anti-p53 antibody (DO-1, Santa Cruz Biotechnology) and incubated with rotation at 4ºC overnight. 25 µl of protein A/G magnetic beads (Invitrogen) were added into each reaction for an additional 2-hour incubation. After the resin was washed 4 times with IP buffer, protein complexes were eluted with 60 µl of 2X SDS-PAGE sample buffer and subjected to SDS-PAGE and immunoblotting.
Western blot
Cell lysates were either prepared using RIPA buffer (Cell Signaling) supplemented with protease inhibitors (Roche complete mini), followed by 5 min heating at 75°C after addition of 2XSample Loading buffer (100 mM Tris-HCl pH 6.8, 4% SDS, 20% Glycerol, 5% β-mercaptoethanol, 0.2% Bromophenol blue). Alternatively, cells were directly lysed in 2XSample Loading buffer followed by 20 min heating at 95°C. Samples were separated on 4-12% Trisglycine SDS-PAGE gels (Invitrogen), and transferred to PVDF membrane (Millipore). Membranes were blocked for 1hr in TBS buffer with 5% milk and 0.1% Tween 20, followed by overnight incubation with primary antibodies at 4°C. Membranes were washed for 3 x 5min at room temperature in TBS-T buffer. Mouse and rabbit HRP-conjugated secondary antibodies (ThermoFisher, 1:5,000) were incubated for 1 hr at room temperature followed by washing 3 x 5 min at room temperature in TBS-T. For detection, membranes were exposed to Pierce ECL Western Blotting Substrate and detected on Hyblot CL film (Denville Scientific Inc). Overexpression of KDM5A HCT116 cells were transfected with either pcDNA6.2 N-emGFP Dest (empty vector) or pcDNA6.2 N-emGFP-KDM5A(Gong et al., 2017) using Lipofectamine 3000 reagent (Thermo). Following transfection, GFP-positive cells were sterile sorted using flow cytometry and harvested for western blot analysis.
RT-PCR
Affymetrix microarray analysis
RNA was extracted using RNeasy Mini Kit from Qiagen 72-hour after transfection with two different siRNA oligos (siKDM5A#1, siKDM5A#4). siRNA controls were purchased from Dharmacon. After quality control with Agilent RNA analyzer, RNA was subjected to hybridization using an Affymetrix HT HG-U133+ PM 16-Array Plate (for NB-1691 and SK-N-BE2) or HuGene_2.0_st chip for isogenic p53 +/+ and p53 -/-HCT116 cells. The KDM5A knockdown samples were compared with the controls using Gene Set Enrichment Analysis (GSEA). Differential gene expression was analyzed by t-test using the Differential Expression Analysis module at GenePattern server (http://genepattern.broadinstitute.org/gp/pages/protocols/DiffExp.html).
Molecular concept analysis
For molecular concept analysis, the genes upregulated by KDM5A depletion in p53+/+ HCT116 cells were upload into the Oncomine program (www.oncomine.com) and concept analysis was performed. Here we focused on the "molecular subtype mutation" concepts association with KDM5A targets. The associated concepts with odds ratio <2, p value<0.001 were filtered out. The network of the associated concepts was displayed using Cytoscape program (http://cytoscape.org/).
TCGA and cBioportal data analysis for correlation of KDM5A amplification and TP53 mutation
To analyze the copy number alterations of histone demethylases we mined TCGA Tumorscape (http://www.broadinstitute.org/tcga/pages/portalHome.jsf), which is designed to facilitate the use of high-resolution copy number data amassed from multiple cancer types (all generated through TCGA) (Beroukhim et al., 2010) . It enables downloading and interactive viewing of cancer copy-number profiles across several dozen cancer types, gene-level queries to determine the rate and significance of alteration of every gene, and cancer-type-level queries to identify the significant regions of copy-number alteration. To investigate the mutual exclusivity of genetic alterations of TP53 and KDM5A, we used the UCSC Xena program (https://xenabrowser.net) to download the data that contained gene copy calculations from the cohort of TCGA Pan-Cancer (PANCAN). We downloaded the gene-level copy number (gistic2_thresholded) of KDM5A, MDM2 and TP53. We then downloaded somatic non-silent TP53 mutations (gene-level) from the dataset of "somatic gene-level non-silent mutation (ucsc) data" from the PANCAN cohort. After combining all data together, we had 2623 samples that consisted of calculated data for both KDM5A and TP53. To examine the relationship of KDM5A amplification and TP53 somatic mutation, we excluded samples that had TP53 deletion with both alleles, resulting in 2575 cases for analysis. We then calculated the frequency difference using contingency table for Fisher's exact test by using Prism software. For Figure 1G and 1H, we employed genetic alteration data by using cBioportal program (http://www.cbioportal.org/). We combined 6 different types of cancers including low grade gloma (TCGA, provisional), lung squamous cell carcinoma (TCGA, provisional), ovarian cancer (TCGA, provisional), neuroendocrine prostate cancer (Trento/Cornell/Broad 2016), testicular germ cell cancer (TCGA, provisional), which had a higher incidence of KDM5A amplification (>5%) than other types of cancer.
Data mining
The expression of KDM5A from RNA-seq (GSE62564) was downloaded from R2 program and analyzed by one-way ANOVA using Prism software. A Kaplan-Meier survival curve was generated using R2 program (http://r2.amc.nl). The median value of KDM5A expression was used for the cut-off level of KDM5A expression in survival analysis. For connectivity map analysis, the common genes upregulated and downregulated by KDM5A knockdown in both p53+/+ and p53-/-HCT116 cells were uploaded into program (https://clue.io/) for connectivity map analysis.
ChIP-seq
To detect the genomic enrichment of H3K4me3 and KDM5A, 2X10 7 HCT116 cells (2 clones for CRISPR controls, 2 clones for CRISPR KDMA) were cross-linked for 5 min with 1% formaldehyde, quenched with 125 mM glycine for 5 min, washed in cold PBS, and resuspended in Cell Lysis Buffer (10 mM Tris-HCl pH 8.0, 10 mM NaCl, 0.2% NP40, and protease inhibitors). The nuclear pellet was resuspended with Nuclei Lysis Buffer (50 mM Tris-HCl pH 8.0, 10 mM EDTA, 1% SDS, and protease inhibitors). Chromatin fragments (100-300 bp) obtained by sonication (Covaris) were resuspended in 150 mM NaCl, 20 mM Tris-HCl pH 8.0, 2 mM EDTA, and 1% Triton X-100, 0.01% SDS then incubated for 4 hours at 4°C with magnetic beads (Dynal) conjugated to H3K4me3 (07-473, EMD Millipore) or KDM5A (A300-897, Bethyl Laboratory). Beads were washed, DNA was eluted, and cross-links were reversed in 1% SDS and 0.1 M NaHCO3 overnight at 65°C. DNA was purified using a PCR purification kit (Qiagen). Libraries were prepared from the ChIP material using the ChIP-Seq Sample Prep Kit (Illumina) and sequenced on Illumina HiSeq 2000 (50-bp reads). BWA (version 0.5.9-r26-dev, default parameters) was used to align both input and sample ChIPseq reads to the hg19 reference genome (GRCh37-lite). Duplicated reads were marked using Picard (version 1.65(1160)) (http://picard.sourceforge.net). Samtools (version: 0.1.17 (r973:277)) with the -q 1 -F 1024 parameters was used to exclude duplicated reads. For quality control (QC) purposes and to estimate fragment size, SPP (version 1.11, for samples with duplicates removed) was used to generate cross-correlation plots using R (version 2.14.0) with the caTools(version 1.17) and bitops (version 1.0-6) packages. All data passed QC following ENCODE criterion. BAM files were converted to BED files using bamToBed (Bedtools version 2.17.0). The fragment sizes estimated by SPP were used to extend each read in a new BED file. Per base coverage was determined with genomeCoverageBed (Bedtools) and scaled to 15 million reads total. A bigwig file for viewing within the Integrative Genome Viewer (IGV) (version 2.3.57 (84)) was generated using bedGraphToBigWig (Bedtools). MACS2 (version 2.0.9 20111102, nomodel with extsize defined as fragment size estimated by SPP) was used to call peaks from the original BED file generated above. For each each different ChIP-Seq experiment
Click-iT Labeling Assay for Metabolic Labeling of Newly Synthesized Proteins
Cells were plated at 5 million cells per 100mm dish in DMEM supplemented with 10% FBS. Cells were washed with warm PBS and replaced with methionine-free medium (Thermo 21013024 supplement with glutamine and sodium pyruvate) for 1 hour at 37 o C 5% CO 2 . Following, fresh methionine-free media containing 50uM of Click-iT AHA (L-azidohomoalanine) (Thermo C10102) was added to the cells for 2 hours at 37 o C. After AHA-labeling, cells were washed with warm PBS and lysed with 1% SDS, 50mM Tris-HCl, (pH 8.0) supplemented with phosphatase (PhosSTOP, Sigma) and protease (cOmplete mini, Roche) by applying the buffer directly to the plate, incubating the cells on ice for 30 minutes, tilting the plates, and collecting the lysate. Lysates were briefly sonicated, vortexed for 5 minutes, and centrifuged at 18,000xg for 5 minutes at 4 o C. Total protein quantification was assayed using the EZQ Protein Quantification Kit (Thermo R33200) according to the manufacturer's protocol and results were read on a fluorescence-based microplate reader (BioTek Synergy 2). Click chemistry of the biotin-alkyne (PEG4 carboxamide-propargyl biotin) (Thermo B10185) to the AHA-labeled lysates was performed using the Click-iT Protein Reaction Buffer Kit (Thermo C10276) using a concentration of 40uM biotin-alkyne per click reaction (and no biotin-alkyne added for controls). Following the click reaction, samples were either assayed for total biotinylated protein by following the manufacturer's protocol or directly continued after the click reaction for immunoprecipitation. For total biotinylated protein, briefly, 600uL of methanol, 150uL of chloroform, and 400uL of megaOhm water was sequentially added and vortexed, followed by centrifugation at 18,000xg for 5 minutes. The upper aqueous phase was discarded, and 450uL of methanol was added, vortexed, and centrifuged again at 18,000xg for 5 minutes. This methanol step was performed in duplicate to remove residual reaction components. Protein pellets were allowed to air dry and resuspended in a suitable volume of sample buffer and heated prior to western blot analysis. For immunoprecipitation, 2ug of anti-p53 antibody (DO-1; Santa Cruz; sc126) was bound to 10uL of magnetic beads per sample (Dynabeads M280 Sheep anti-mouse IgG (Invitrogen, 11201D)) for 1 hour in PBS. Beads were subsequently washed and added directly to the click reaction step along with 800uL of RIPA buffer (Thermo 89900) and left to rotate end-over-end at 4 o C overnight. The following day, beads were washed 3 times with RIPA buffer and eluted with sample buffer at 95 o C for 25 minutes.
RNA-immunoprecipitation
RNA immunoprecipitation was performed as previously described (Rinn et al., 2007) . Briefly, 2.5 ug V5 antibody (Invitrogen) or control mouse IgG and 20ul of Protein A/G plus beads (Thermo Scientific) were incubated with 2mg of p53+/+ HCT116 cell lysate transfected with eIF4A2 plasmid, and incubated for 3 hrs at 4 0 C with gentle rotation. The beads were then washed five times with RIP buffer, and the RNAs were extracted with Trizol reagent (Invitrogen), followed by standard RNA precipitation protocols. The RNA was resuspended in 30 μl of RNase-free water and subjected for PCR analysis. A fraction of immunoprecipitated protein were used for western blotting to confirm the immunoprecipitation.
Luciferase reporter assay
After 24 hour siRNA knockdown of KDM5A in p53++ and p53-/-HCT116 cells by reverse transfection in 6-well plate, 2.4m fter 24 hour siRNA knluciferease reporter plasmid (145-pGL3ctrl-3' UTR, addgene# 28175) (Chen and Kastan, 2010) and 0.1m anpRL Renilla Luciferase Control Reporter Vector (Promega) were transfected by Lipofectamine™ 3000 Transfection Reagent (Invitrogen). 48 hours later, cells were harvested for the dual luciferase assay according to the instructions of manufacturer (Promega).
Animal experiments
All murine experiments were done in accordance with a protocol approved by the Institutional Animal Care and Use Committee of St. Jude Children's Research Hospital. Lentivirus was used to transduce isogenic p53 +/+ and p53 -/-HCT116, SK-N-SH, BE2(C) and NB-1691 cells for shRNA knockdown of KDM5A. After transduction, 1 μg/ml of puromycin was used for selection of stable knockdown. Subcutaneous xenografts were established in male CB-17 severe combined immunodeficient mice (Taconic, Hudson, NY). Tumors measurements were performed weekly using handheld calipers, and volumes calculated as width π/6 xd3 where d is the mean of two diameters taken at right angles.
Statistical Analysis
For Figure 1b and 1c, the mutual exclusivity of pairs of mutations was evaluated with the use of two-by-two contingency tables and Chi-square test. A p value of less than 0.05 was considered statistically significant. Analyses were conducted in R-3.2.5. Each experiment was carried out at least in triplicate. To determine statistical significance, the unpaired, two-tailed Student's t test was calculated using the t test calculator available on GraphPad Prism 7.0 software. Fisher's exact test was performed for frequency distribution in contingency table. A p value of less than 0.05 was considered statistically significant. Tumor growth statistical comparisons were performed by ANOVA using PRISM program.
Data and Software Availability
All microarray and deep sequencing data have been deposited in GEO under accession number: GSE45967, GSE49854, GSE100511, GSE107221.
